105 related articles for article (PubMed ID: 37128507)
1. Retrospective examination of pseudoprogression in
Wetzel EA; Farrell MJ; Eldred BSC; Liu V; Saha I; Zapanta Rinonos S; Prins T; Li T; Cao M; Hegde J; Kaprealian T; Khanlou N; Liau LM; Nghiemphu PL; Cloughesy TF; Chong RA; Ellingson BM; Lai A
Neurooncol Adv; 2023; 5(1):vdad028. PubMed ID: 37128507
[TBL] [Abstract][Full Text] [Related]
2. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Dworkin M; Mehan W; Niemierko A; Kamran SC; Lamba N; Dietrich J; Martinez-Lage M; Oh KS; Batchelor TT; Wen PY; Loeffler JS; Shih HA
J Neurooncol; 2019 Mar; 142(1):69-77. PubMed ID: 30488294
[TBL] [Abstract][Full Text] [Related]
3. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
[TBL] [Abstract][Full Text] [Related]
4. Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.
Lin AL; White M; Miller-Thomas MM; Fulton RS; Tsien CI; Rich KM; Schmidt RE; Tran DD; Dahiya S
J Neurooncol; 2016 Dec; 130(3):529-533. PubMed ID: 27704386
[TBL] [Abstract][Full Text] [Related]
5. Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma.
Bronk JK; Guha-Thakurta N; Allen PK; Mahajan A; Grosshans DR; McGovern SL
Clin Transl Radiat Oncol; 2018 Feb; 9():30-34. PubMed ID: 29594248
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.
Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H
NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932
[TBL] [Abstract][Full Text] [Related]
7. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.
Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS
AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259
[TBL] [Abstract][Full Text] [Related]
8. Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study.
Seyve A; Dehais C; Chinot O; Djelad A; Cohen-Moyal E; Bronnimann C; Gourmelon C; Emery E; Colin P; Boone M; Vauléon E; Langlois O; di Stefano AL; Seizeur R; Ghiringhelli F; D'Hombres A; Feuvret L; Guyotat J; Capelle L; Carpentier C; Garnier L; Honnorat J; Meyronet D; Mokhtari K; Figarella-Branger D; Ducray F
Neuro Oncol; 2023 Mar; 25(3):495-507. PubMed ID: 35953421
[TBL] [Abstract][Full Text] [Related]
9. IDH1
Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
[TBL] [Abstract][Full Text] [Related]
10. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
Nam YK; Park JE; Park SY; Lee M; Kim M; Nam SJ; Kim HS
Eur Radiol; 2021 Oct; 31(10):7374-7385. PubMed ID: 34374800
[TBL] [Abstract][Full Text] [Related]
11. A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma.
Kebir S; Schmidt T; Weber M; Lazaridis L; Galldiks N; Langen KJ; Kleinschnitz C; Hattingen E; Herrlinger U; Lohmann P; Glas M
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33105661
[TBL] [Abstract][Full Text] [Related]
12. A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patients.
Moassefi M; Faghani S; Conte GM; Kowalchuk RO; Vahdati S; Crompton DJ; Perez-Vega C; Cabreja RAD; Vora SA; Quiñones-Hinojosa A; Parney IF; Trifiletti DM; Erickson BJ
J Neurooncol; 2022 Sep; 159(2):447-455. PubMed ID: 35852738
[TBL] [Abstract][Full Text] [Related]
13. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
14. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
[TBL] [Abstract][Full Text] [Related]
15. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.
Sidibe I; Tensaouti F; Gilhodes J; Cabarrou B; Filleron T; Desmoulin F; Ken S; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lotterie JA; Roques M; Péran P; Cohen-Jonathan Moyal E; Laprie A
Radiother Oncol; 2023 Apr; 181():109486. PubMed ID: 36706959
[TBL] [Abstract][Full Text] [Related]
16. Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas.
Cho NS; Hagiwara A; Eldred BSC; Raymond C; Wang C; Sanvito F; Lai A; Nghiemphu P; Salamon N; Steelman L; Hassan I; Cloughesy TF; Ellingson BM
Neurooncol Adv; 2022; 4(1):vdac124. PubMed ID: 36033919
[TBL] [Abstract][Full Text] [Related]
17. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
18. Mean apparent propagator-MRI in evaluation of glioma grade, cellular proliferation, and IDH-1 gene mutation status.
Sun Y; Su C; Deng K; Hu X; Xue Y; Jiang R
Eur Radiol; 2022 Jun; 32(6):3744-3754. PubMed ID: 35076759
[TBL] [Abstract][Full Text] [Related]
19. Clinical Imaging for Diagnostic Challenges in the Management of Gliomas: A Review.
Bonm AV; Ritterbusch R; Throckmorton P; Graber JJ
J Neuroimaging; 2020 Mar; 30(2):139-145. PubMed ID: 31925884
[TBL] [Abstract][Full Text] [Related]
20. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]